JP2018118953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018118953A5 JP2018118953A5 JP2017115832A JP2017115832A JP2018118953A5 JP 2018118953 A5 JP2018118953 A5 JP 2018118953A5 JP 2017115832 A JP2017115832 A JP 2017115832A JP 2017115832 A JP2017115832 A JP 2017115832A JP 2018118953 A5 JP2018118953 A5 JP 2018118953A5
- Authority
- JP
- Japan
- Prior art keywords
- linking group
- group
- antibody
- formula
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000005647 linker group Chemical group 0.000 claims description 98
- 229940079593 drug Drugs 0.000 claims description 55
- 239000003814 drug Substances 0.000 claims description 55
- 150000003573 thiols Chemical class 0.000 claims description 47
- 239000000611 antibody drug conjugate Substances 0.000 claims description 44
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 44
- 239000003795 chemical substances by application Substances 0.000 claims description 35
- 238000000638 solvent extraction Methods 0.000 claims description 34
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 25
- -1 maleimido-caproyl Chemical group 0.000 claims description 18
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 17
- 229960002173 citrulline Drugs 0.000 claims description 13
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims description 13
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 claims description 10
- 108010045524 dolastatin 10 Proteins 0.000 claims description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 10
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 9
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 9
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 8
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 8
- 229940127093 camptothecin Drugs 0.000 claims description 8
- 235000018417 cysteine Nutrition 0.000 claims description 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 8
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 7
- 235000001014 amino acid Nutrition 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 125000003827 glycol group Chemical group 0.000 claims description 7
- 229960003048 vinblastine Drugs 0.000 claims description 7
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 4
- 108010016626 Dipeptides Proteins 0.000 claims description 3
- 108010044540 auristatin Proteins 0.000 claims description 3
- 229960003405 ciprofloxacin Drugs 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004434 sulfur atom Chemical group 0.000 claims 4
- 229940125644 antibody drug Drugs 0.000 claims 3
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 2
- 235000013477 citrulline Nutrition 0.000 claims 2
- 239000000562 conjugate Substances 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- DALMAZHDNFCDRP-VMPREFPWSA-N 9h-fluoren-9-ylmethyl n-[(2s)-1-[[(2s)-5-(carbamoylamino)-1-[4-(hydroxymethyl)anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound O=C([C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(C)C)NC1=CC=C(CO)C=C1 DALMAZHDNFCDRP-VMPREFPWSA-N 0.000 description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
Priority Applications (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW112149061A TW202435918A (zh) | 2016-12-14 | 2017-12-14 | 多重藥物之抗體藥物結合物 |
| CN201780077877.2A CN110167355A (zh) | 2016-12-14 | 2017-12-14 | 多药抗体药物偶联物 |
| MX2019006983A MX2019006983A (es) | 2016-12-14 | 2017-12-14 | Conjugados de anticuerpo-farmaco de multiples farmacos. |
| EP17879927.6A EP3554266A4 (en) | 2016-12-14 | 2017-12-14 | ANTIBODY-DRUG CONJUGATES MULTI-DRUG |
| KR1020197020269A KR20190095374A (ko) | 2016-12-14 | 2017-12-14 | 다중-약물 항체 약물 컨쥬게이트 |
| AU2017376926A AU2017376926C1 (en) | 2016-12-14 | 2017-12-14 | Multi-drug antibody drug conjugates |
| KR1020247025440A KR20240119181A (ko) | 2016-12-14 | 2017-12-14 | 다중-약물 항체 약물 컨쥬게이트 |
| IL308672A IL308672A (en) | 2016-12-14 | 2017-12-14 | Multi-drug antibody drug conjugates |
| US16/463,541 US11541128B2 (en) | 2016-12-14 | 2017-12-14 | Multi-drug antibody drug conjugates |
| NZ753550A NZ753550B2 (en) | 2017-12-14 | Multi-drug antibody drug conjugates | |
| TW106144020A TWI828614B (zh) | 2016-12-14 | 2017-12-14 | 多重藥物之抗體藥物結合物 |
| CN202310259438.0A CN116271080A (zh) | 2016-12-14 | 2017-12-14 | 多药抗体药物偶联物 |
| IL267003A IL267003B2 (en) | 2016-12-14 | 2017-12-14 | Multi-Drug Antibody Drug Conjugates Comprising An Antibody And Linking Assembly Units Having Anti-Cancer Drug Units |
| PCT/US2017/066504 WO2018112253A1 (en) | 2016-12-14 | 2017-12-14 | Multi-drug antibody drug conjugates |
| MA050755A MA50755A (fr) | 2016-12-14 | 2017-12-14 | Conjugués anticorps-médicaments mult-médicaments |
| CA3043931A CA3043931A1 (en) | 2016-12-14 | 2017-12-14 | Multi-drug antibody drug conjugates |
| US18/054,497 US20240033372A1 (en) | 2016-12-14 | 2022-11-10 | Multi-drug antibody drug conjugates |
| JP2023037167A JP2023071996A (ja) | 2016-12-14 | 2023-03-10 | 多剤抗体薬物コンジュゲート |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434333P | 2016-12-14 | 2016-12-14 | |
| US62/434,333 | 2016-12-14 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023037167A Division JP2023071996A (ja) | 2016-12-14 | 2023-03-10 | 多剤抗体薬物コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018118953A JP2018118953A (ja) | 2018-08-02 |
| JP2018118953A5 true JP2018118953A5 (enExample) | 2020-07-30 |
| JP7244987B2 JP7244987B2 (ja) | 2023-03-23 |
Family
ID=63044836
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017115832A Active JP7244987B2 (ja) | 2016-12-14 | 2017-06-13 | 多剤抗体薬物コンジュゲート |
| JP2023037167A Pending JP2023071996A (ja) | 2016-12-14 | 2023-03-10 | 多剤抗体薬物コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023037167A Pending JP2023071996A (ja) | 2016-12-14 | 2023-03-10 | 多剤抗体薬物コンジュゲート |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11541128B2 (enExample) |
| EP (1) | EP3554266A4 (enExample) |
| JP (2) | JP7244987B2 (enExample) |
| KR (2) | KR20240119181A (enExample) |
| CN (2) | CN116271080A (enExample) |
| AU (1) | AU2017376926C1 (enExample) |
| CA (1) | CA3043931A1 (enExample) |
| IL (2) | IL267003B2 (enExample) |
| MA (1) | MA50755A (enExample) |
| MX (1) | MX2019006983A (enExample) |
| TW (2) | TWI828614B (enExample) |
| WO (1) | WO2018112253A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019091384A1 (en) * | 2017-11-08 | 2019-05-16 | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. | Conjugates of biomolecule and use thereof |
| US11865182B2 (en) * | 2017-11-18 | 2024-01-09 | Nzola DE MAGALHAES | Product and process for employing GC7 (N1-guanyl-1,7-diaminoheptane) based antigen binding conjugates in cancer therapy |
| MA52669A (fr) * | 2018-04-06 | 2021-02-17 | Seagen Inc | Conjugués peptidiques de camptothécine |
| TW202519270A (zh) | 2018-06-07 | 2025-05-16 | 美商思進公司 | 喜樹鹼結合物 |
| CN111378006A (zh) * | 2018-12-28 | 2020-07-07 | 联宁（苏州）生物制药有限公司 | 一种用于抗体偶联药物的新型双臂中间体lnd1026-035及其合成方法 |
| JP7232925B2 (ja) * | 2019-02-15 | 2023-03-03 | ウーシー バイオロジクス アイルランド リミテッド | 改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス |
| US12109273B2 (en) | 2019-02-15 | 2024-10-08 | Wuxi Xdc Singapore Private Limited | Process for preparing antibody-drug conjugates with improved homogeneity |
| CN112569368A (zh) * | 2019-08-07 | 2021-03-30 | 烟台迈百瑞国际生物医药股份有限公司 | 一种抗体药物偶联物及其应用 |
| CA3166732A1 (en) * | 2020-01-22 | 2021-07-29 | Medimmune Limited | Compounds and conjugates thereof |
| IL298155A (en) * | 2020-05-13 | 2023-01-01 | Seagen Inc | Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates |
| CN111560078A (zh) * | 2020-06-19 | 2020-08-21 | 联宁（苏州）生物制药有限公司 | 具有马来酰亚胺接头的双臂中间体及其合成方法 |
| CN113941007B (zh) * | 2020-07-16 | 2024-06-07 | 成都科岭源医药技术有限公司 | 一种串联的双药物链接组装单元及其应用 |
| CN114053426B (zh) * | 2020-07-30 | 2024-06-18 | 成都科岭源医药技术有限公司 | 一种双药链接组装单元及双药靶向接头-药物偶联物 |
| CN111892575B (zh) * | 2020-08-20 | 2024-10-01 | 南京大学 | 一类紫草宁硫辛硫醚孪药分子及其合成方法和应用 |
| CN115105607B (zh) * | 2021-03-22 | 2024-12-20 | 成都科岭源医药技术有限公司 | 一种用于adc的双药-接头的制备方法及其用途 |
| EP4323009A4 (en) | 2021-04-14 | 2025-03-05 | Genequantum Healthcare (Suzhou) Co., Ltd. | Linkers, conjugates and applications thereof |
| CN117157098A (zh) * | 2021-06-22 | 2023-12-01 | 荣昌生物制药(烟台)股份有限公司 | 一种药物组合及其用途 |
| AU2021225125B9 (en) * | 2021-07-19 | 2023-02-02 | Mabplex International Co., Ltd. | Antibody drug conjugate loaded with binary toxins and its application |
| EP4400121A1 (en) | 2021-09-03 | 2024-07-17 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| US11814394B2 (en) | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
| CA3255303A1 (en) * | 2022-04-14 | 2023-10-19 | Debiopharm Research & Manufacturing S.A. | Combining ligand and a drug with enhanced pharmacokinetic and release properties |
| EP4525927A1 (en) * | 2022-05-20 | 2025-03-26 | Novartis AG | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| CA3252208A1 (en) * | 2022-05-20 | 2023-11-23 | Novartis Ag | ANTIBODY-DRUG CONJUGATES |
| JP2025523605A (ja) * | 2022-06-28 | 2025-07-23 | ジェネクアンタム・ヘルスケア・（スージョウ）・カンパニー・リミテッド | 抗ｆｇｆｒ３抗体コンジュゲート及びその医療用途 |
| WO2024005123A1 (ja) | 2022-06-30 | 2024-01-04 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| KR20250039376A (ko) * | 2022-07-15 | 2025-03-20 | 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. | 링커, 컨쥬게이트 및 이의 적용 |
| WO2024078449A1 (en) | 2022-10-09 | 2024-04-18 | LaNova Medicines Limited | Compounds, compositions and methods |
| CN115737834A (zh) * | 2022-11-11 | 2023-03-07 | 山东大学 | 一种抗体偶联药物cea-海兔毒素10衍生物及其在抗肿瘤中的应用 |
| AR132368A1 (es) | 2023-04-18 | 2025-06-18 | Astrazeneca Ab | Conjugados que comprenden enlazadores escindibles |
| WO2025031307A1 (zh) * | 2023-08-04 | 2025-02-13 | 上海华藕生物医药有限公司 | 多药连接体及抗体药物偶联物 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| JP2763020B2 (ja) | 1995-04-27 | 1998-06-11 | 日本電気株式会社 | 半導体パッケージ及び半導体装置 |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| RU2199347C2 (ru) | 1996-08-02 | 2003-02-27 | Орто-Макнейл Фармасьютикал, Инк. | Полипептиды, обладающие единственным ковалентно связанным n-концевым водорастворимым полимером |
| PT2357006E (pt) | 2002-07-31 | 2016-01-22 | Seattle Genetics Inc | Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| SG149815A1 (en) | 2003-11-06 | 2009-02-27 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| WO2005112919A2 (en) | 2004-05-19 | 2005-12-01 | Medarex, Inc. | Self-immolative linkers and drug conjugates |
| CN101203241B (zh) | 2005-04-19 | 2012-02-22 | 西雅图基因公司 | 人源化抗-cd70结合物和其应用 |
| US20060292616A1 (en) | 2005-06-23 | 2006-12-28 | U.S. Genomics, Inc. | Single molecule miRNA-based disease diagnostic methods |
| LT1912671T (lt) | 2005-07-18 | 2017-12-11 | Seattle Genetics, Inc. | Vaisto konjugatai, turintys gliukoronido linkerį |
| PL1813614T3 (pl) | 2006-01-25 | 2012-03-30 | Sanofi Sa | Środki cytotoksyczne zawierające nowe pochodne tomaymycyny |
| US8257706B2 (en) | 2006-08-25 | 2012-09-04 | Seattle Genetics, Inc. | CD30 binding agents and uses thereof |
| AU2008251608B2 (en) | 2007-05-08 | 2014-03-27 | Genentech, Inc. | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
| SI2211904T1 (sl) | 2007-10-19 | 2016-12-30 | Seattle Genetics, Inc. | CD19 vezavna sredstva in njihove uporabe |
| HUE035182T2 (hu) | 2008-03-18 | 2018-05-02 | Genentech Inc | Anti-HER2 antitest-hatóanyag-konjugátum és pertuzumab kombinációi |
| CN108727407B (zh) | 2009-02-05 | 2022-01-28 | 伊缪诺金公司 | 新型苯并二氮杂䓬衍生物 |
| FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| US9849192B2 (en) * | 2009-11-18 | 2017-12-26 | Rutgers, The State University Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| TWI540136B (zh) | 2010-04-15 | 2016-07-01 | 梅迪繆思有限公司 | 吡咯并苯并二氮呯及其共軛物 |
| AU2011265054B2 (en) | 2010-06-08 | 2016-09-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| WO2012112708A1 (en) | 2011-02-15 | 2012-08-23 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and methods of preparation |
| AU2013221585B2 (en) | 2012-02-17 | 2017-03-30 | Seagen Inc. | Antibodies to integrin alphavbeta6 and use of same to treat cancer |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| NZ741211A (en) | 2012-05-15 | 2019-09-27 | Seattle Genetics Inc | Self-stabilizing linker conjugates |
| KR102538993B1 (ko) | 2013-10-15 | 2023-06-02 | 씨젠 인크. | 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커 |
| CA2934030A1 (en) | 2013-10-15 | 2015-04-23 | Sorrento Therapeutics Inc. | Drug-conjugates with a targeting molecule and two different drugs |
| KR102462811B1 (ko) * | 2015-04-27 | 2022-11-04 | 에이비온 주식회사 | 항체에 덴드론이 접합된 면역접합체 및 이의 용도 |
| RU2695062C2 (ru) * | 2015-05-22 | 2019-07-19 | Общество С Ограниченной Ответственностью "Отечественные Фармацевтические Технологии" | Новые производные 3,5-дивинил-пиразола для медицинского применения |
-
2017
- 2017-06-13 JP JP2017115832A patent/JP7244987B2/ja active Active
- 2017-12-14 IL IL267003A patent/IL267003B2/en unknown
- 2017-12-14 CN CN202310259438.0A patent/CN116271080A/zh active Pending
- 2017-12-14 MA MA050755A patent/MA50755A/fr unknown
- 2017-12-14 TW TW106144020A patent/TWI828614B/zh not_active IP Right Cessation
- 2017-12-14 AU AU2017376926A patent/AU2017376926C1/en active Active
- 2017-12-14 MX MX2019006983A patent/MX2019006983A/es unknown
- 2017-12-14 WO PCT/US2017/066504 patent/WO2018112253A1/en not_active Ceased
- 2017-12-14 US US16/463,541 patent/US11541128B2/en active Active
- 2017-12-14 IL IL308672A patent/IL308672A/en unknown
- 2017-12-14 CA CA3043931A patent/CA3043931A1/en active Pending
- 2017-12-14 TW TW112149061A patent/TW202435918A/zh unknown
- 2017-12-14 CN CN201780077877.2A patent/CN110167355A/zh active Pending
- 2017-12-14 KR KR1020247025440A patent/KR20240119181A/ko not_active Withdrawn
- 2017-12-14 EP EP17879927.6A patent/EP3554266A4/en not_active Withdrawn
- 2017-12-14 KR KR1020197020269A patent/KR20190095374A/ko not_active Ceased
-
2022
- 2022-11-10 US US18/054,497 patent/US20240033372A1/en active Pending
-
2023
- 2023-03-10 JP JP2023037167A patent/JP2023071996A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018118953A5 (enExample) | ||
| JP7330309B2 (ja) | 改善されたリガンド－薬物コンジュゲート薬物動態のためのｐｅｇ化薬物－リンカー | |
| JP7244987B2 (ja) | 多剤抗体薬物コンジュゲート | |
| WO2009150284A3 (es) | Conjugados de apo-a para la administración de compuestos biológicamente activos | |
| UA103758C2 (ru) | Конъюгаты олигомеров инсулина, их композиции и применение | |
| WO2017031034A3 (en) | Covalent linkers in antibody-drug conjugates and methods of making and using the same | |
| RU2018136778A (ru) | Пролекарства цитотоксических лекарственных средств, содержащие ферментативно расщепляемые группы | |
| IL135148A0 (en) | A polysaccharide conjugate and pharmaceutical compositions containing the same | |
| JP2017537893A5 (enExample) | ||
| WO2022015880A3 (en) | T-cell modulatory polypeptides with conjugation sites and methods of use thereof | |
| WO2007100385A3 (en) | Macrocyclic depsipeptide antibody-drug conjugates and methods | |
| WO2016064749A3 (en) | Antibody-drug conjugates and related compounds, compositions, and methods of use | |
| WO2007062610A3 (es) | Dendrímero con peg de cuatro ramas para la conjugación a proteínas y péptidos | |
| JP2017525750A (ja) | ジスルフィド含有タンパク質からコンジュゲートを作製するための方法 | |
| BR112020005605A2 (pt) | novos conjugados de amanitina direcionados a psma | |
| MX2023010099A (es) | Enlazadores ramificados para conjugados de anticuerpo-fármaco y métodos de uso de estos. | |
| WO2004050711A3 (en) | Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof | |
| WO2005027828A3 (en) | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof | |
| Zhang et al. | Molecular-weight-dependent pharmacokinetics and cytotoxic properties of cisplatin complexes prepared with chondroitin sulfate A and C | |
| EP2014306A3 (en) | Metal-polysaccharide conjugates: compositions and synthesis | |
| WO2004018499A3 (en) | Synthetic heparin-binding growth factor analogs | |
| WO2005002516A3 (en) | Leukocyte internalized peptide-drug conjugates | |
| WO2023154564A3 (en) | Cd206 targeted peptide conjugates and methods of using the same | |
| WO2025049634A8 (en) | Glycan conjugate compositions and methods | |
| WO2024086767A3 (en) | Glycan conjugate compositions and methods |